Clinical Trials Drive Breast Cancer Progress as Awareness Month Highlights New Research
The Alliance for Clinical Trials in Oncology marks Breast Cancer Awareness Month with eight active trials spanning treatment de-escalation, survivorship ...
Tag: pembrolizumab)
Engineered Dendritic Cell Vaccine Draws Immune Cells Into Lung Tumors but Falls Short of Shrinkage
A phase I trial found that a CCL21-engineered dendritic cell vaccine combined with pembrolizumab safely increased T cell infiltration in ...
When Cancer Drugs Leak: First Surgical Case of EV-P Extravasation Reported
A rare but serious infusion accident has been documented for the first time in the medical literature. Urologists at University ...
Lower Lenvatinib Starting Doses Show No Clear Advantage in Advanced Endometrial Cancer
A new systematic review and meta-analysis finds that starting lenvatinib below 20 mg with pembrolizumab neither clearly preserves tumor response ...
When Cancer Immunotherapy Silences the Thyroid Twice: A Rare One-Two Endocrine Blow
A new case report describes a pembrolizumab-treated patient who developed primary hypothyroidism from immune thyroid destruction followed by rare isolated ...
First-in-Human Trial Shows Synthetic Immune Cell Activator IMM60 Is Safe in Advanced Cancer
A first-in-human phase I trial found that the liposomal iNKT cell agonist IMM60, given alone or with pembrolizumab, was well ...
When Tumors Hide Their Flags, Natural Killer Cells May Take Over Against Colorectal Cancer
Two patients with microsatellite-unstable metastatic colorectal cancer and markedly reduced HLA-I expression achieved durable responses to pembrolizumab, suggesting that NK ...
Immunotherapy Boost for Bile Duct Cancer Survival Holds Firm After Three Years
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
Two Approved Companion Diagnostics Validate Pembrolizumab Eligibility Across dMMR/MSI-H Tumors
Bridging studies confirm that the Ventana MMR RxDx Panel and FoundationOne CDx reliably identify dMMR/MSI-H tumor patients likely to respond ...
Experimental Drug Tolinapant Boosts Immunotherapy Response in Advanced Solid Tumors
A phase I trial found that the IAP antagonist tolinapant combined with pembrolizumab was well tolerated and produced a 33 ...
Radiotherapy Still Matters in dMMR Endometrial Cancer, Researchers Warn in the Immunotherapy Era
A new Viewpoint in eClinicalMedicine argues that immune checkpoint inhibitors have not yet proven they can replace pelvic radiotherapy in ...
Scientists Uncover Why Esophageal Cancer Shrugs Off PD-1 Blockade
A new study shows that the protein SIRPα, produced by esophageal cancer cells themselves, fuels both tumor growth and T-cell ...
Hidden Fibroblast Subtype Drives Lung Cancer Growth and Weakens Immunotherapy
A multimodal single-cell and spatial study has uncovered a collagen-producing fibroblast subtype enriched in EGFR-mutant non-small cell lung cancer that ...
Real-World Data Confirm Immunotherapy Boost for Aggressive Early Breast Cancer
A real-world study of 95 patients in Tokyo confirms that pembrolizumab combined with chemotherapy before and after surgery delivers event-free ...
Immune Booster Cells Show Promise After Checkpoint Blockers in Liver Cancer
A Taiwanese preliminary study found that following a short course of immune checkpoint inhibitors with infusions of tumor-primed dendritic cells ...
Neoadjuvant Chemoimmunotherapy Boosts Stage III Lung Cancer Outcomes
In a groundbreaking advancement for the treatment of stage III locally advanced non-small cell lung cancer (NSCLC), recent research highlights ...
POPULAR NEWS
-
Scientists Reprogram Adult Blood Cells into Stem-Like Colonies Using Episomal Plasmids
-
Study Links Medical Resident Burnout to Training Culture and Workload in Ecuador
-
Nigeria’s Chronic Disease Primary Care Integration Lacks Dedicated National Policy Framework
-
Atomic Interface Engineering Proposed to Improve Selective Carbon Dioxide Conversion to Ethanol